Table 2.

Synthetic EPO 15- or 16-mer peptides (with 10 residue overlaps) able to stimulate human TCLs

Peptide numberPeptide sequence
1APPRL ICDSR VLERY
2ICDSR VLERY LLEAK
3VLERY LLEAK EAENI
4LLEAK EAENI TTGCA
5EAENI TTGCA EHCSL
6TTGCA EHCSL NENIT
7EHCSL NENIT VPDTK
8NENIT VPDTK VNFYA
9VPDTK VNFYA WKRME
10VNFYA WKRME VGQQA
11WKRME VGQQA VEVWQ
12VGQQA VEVWQ GLALL
13VEVWQ GLALL SEAVL
14GLALL SEAVL RGQAL
15SEAVL RGQAL LVNSS
16RGQAL LVNSS QPWEP
17LVNSS QPWEP LQLHV
18QPWEP LQLHV DKAVS
19LQLHV DKAVS GLRSL
20DKAVS GLRSL TTLLR
21GLRSL TTLLR ALGAQ
22TTLLR ALGAQ KEAIS
23ALGAQ KEAIS PPDAA
24KEAIS PPDAA SAAPL
25PPDAA SAAPL RTITA
26SAAPL RTITA DTFRK
27RTITA DTFRK LFRVY
28DTFRK LFRVY SNFLR
29LFRVY SNFLR GKLKL
30SNFLR GKLKL YTGEA
31GKLKL YTGEA CRTGD R
  • Amino acid sequence (single letter code) of rhEPO (contains 166 amino acid residues) with bold residues indicating the main immunogenic epitopes identified in this study: APPRL ICDSR VLERY LLEAK EAENI TTGCA EHCSL NENIT VPDTK VNFYA WKRME VGQQA VEVWQ GLALL SEAVL RGQAL LVNSS QPWEP LQLHV DKAVS GLRSL TTLLR ALGAQ KEAIS PPDAA SAAPL RTITA DTFRK LFRVY SNFLR GKLKL YTGEA CRTGD R.